



# International Journal of Research Publication and Reviews

Journal homepage: [www.ijrpr.com](http://www.ijrpr.com) ISSN 2582-7421

## An Overview: Self Nano Emulsifying Drug Delivery Systems

*Abishek. R<sup>1</sup>, Ajithkumar. M<sup>2</sup>, Azhagumalayan. A<sup>3</sup>, Thanushiya. S<sup>4</sup>, Thendralarasi. U<sup>5</sup>, K. Malarvizhi.<sup>6</sup>*

<sup>1,2,3,4,5</sup> B. Pharm, Pallavan Pharmacy College, Kolivakkam.

<sup>6</sup>M Pharm, Department of Pharmaceutics, Pallavan Pharmacy College, Kanchipuram, 631502

### ABSTRACT:

Autogenous Drug Delivery System (SNEDDS) consists of a uniform mixture of oils, surfactants, and symbiotic fluids that naturally create nanoemulsions in water with gentle agitation in the gastrointestinal fluid. These systems improve solubility, dissolution rate, and oral bioavailability of low-water soluble drugs by promoting rapid release and absorption. SNEDDS has the advantages of improved complication-free preparation, thermodynamic stability, and drug permeability. This gives you an attractive way of delivering lipophilic substances. Current research is focused on refining formulation ingredients, exploring in vivo performance, and creating solid SNEDDS to improve patient adherence and market feasibility.

**KEY WORDS:** SNEDDS, nano-emulsion, bioavailability, poorly water-soluble drugs, oral drug delivery, lipid-based formulations, solubility enhancement, surfactants, drug absorption, solid SNEDDS.

### INTRODUCTION:

Oral routes are the most preferred method for administering chronic drug therapy. Many effective lipophilic drugs have been shown to have low oral bioavailability due to their low water solubility. This group of connections classified by Amidon et al. Due to its low solubility/permeability, intestinal lumen resolution is an important boundary factor in the absorption process. Ongoing research aims to improve oral bioavailability of lipophilic drugs to improve clinical efficacy. A wide range of strategies include the inclusion of active lipophilic components in inactive lipid carriers such as oils, surfactant dispersants, self-emulsifying systems, emulsions, and liposomes, thereby providing each language technique with its own specific advantages and disadvantages. Bioavailability and substantial variability after oral administration. Furthermore, oral drug submission with precipitation, food-drug product interactions, disassembly susceptibility, and early transit metabolism may be associated with all oral bioavailability of bioavailability. Distribution system. Natural or synthetic oils, surfactants, and symbiotic materials, self-nanoemulsal drug delivery system, isotropic mixtures of snedds, and there is a special ability to create oil nanoemulsions in water under gentle agitation, followed by an aqueous medium (3). Nanoscale technology can improve the therapeutic efficacy of drugs in a variety of ways, including: making hydrophobic drugs more soluble:

- Improved permeability or transport of low-permeability drugs (Class III and IV drugs by the Biopharmaceutical Classification System [BCS]) Organic distribution and drug indications.
- Drugs that enable drug reduction drugs enable targeted drug compensation for targeted drug collection (4).



Fig.no:1 BCS classification.

---

**ADVANTAGES:**

- Increased oral bioavailability that permits dosage decrease.
- More stable medication absorption time profiles.
- Drug(s) are selectively targeted towards a certain GIT absorption window.
- Defence of the drug or drugs against the gut's unfriendly environment.
- Delivery profile control.
- Less variation, including the impact of diet.
- Protective of medication compounds that are sensitive.
- Drug payloads are high.
- Doses in liquid or solid form.(1)
- Safeguarding drugs from the harsh conditions within the gastrointestinal tract.
- Therefore, for lipophilic drug substances that show absorption limited by their dissolution rate.
- This could reduce expenses (11).

---

**DISADVANTAGES :**

- Do not take medications administered at very high doses.
- The most demanding drugs supplied as Snedds are those with poor solubility of water and fat.
- The solubility of a drug during the greasy stage has a major effect on the ability of SNEDD to keep the drug in a soluble form.
- When tensile side or pepper water contributes to solubilization of the drug, the risk of precipitation increases.
- Temperature and pH affect the stability of self-nanoemulsal drug delivery systems (3).

---

**COMPOSITION OF SNEDDS :**

The self-emulsifying process relies on:

- The properties of the oil and surfactant mixture
- The amount or proportion of surfactant used
- The specific temperature conditions required for self-emulsification (1)

**DRUG:**

The key factor in formulating SNEDDS is the drug's lipophilicity and hydrophobicity. Ideally, a drug's log P should be around >2. The drug should be administered at a moderate dose and must not experience significant first-pass metabolism (5).

**OIL:**

Long chain triglyceride oils with various satiety levels were used in the formulation of SEDD. The oil improves self-milking, improves lipophilic drug transport through the intestinal lymphatic system, and increases absorption of the gastrointestinal tract. Modified or hydrolyzed herbal oils have played an important role in the effectiveness of SEDD due to their wording and physiological properties. Innovative semi-synthetic medium-chain triglyceride oils have surfactants, increasingly stepping into the squares of traditional medium-chain triglycerides with carbon chains from 12-1 (4).

**SURFACTANT:**

Small surface tension reduces surface tension by creating an interface film that promotes dispersion. When developing SEDD, it is important to take HLB values into consideration. Surfactants with HLB values above 12 are selected to improve emulsification. This helps to spread the intended language quickly by producing small submersible droplets (O/W). Due to its unpaid properties, non-combustible surfactants are often used in Snedds formulations, but can cause slight irreversible changes in the permeability of Git walls. The wording of 30-60% of the surface active ingredients in GIT leads to improved self-emulsification. However, excessive levels of surfactants can cause irritation to the walls of Gi-Tract. (6).

**CO SURFACTANT:**

Communicous density and lytic agents are added to SNEDD to improve pharmaceutical contamination, shorten self-exploitation periods, and adapt the drop size of nanoemulsions. The involvement of symbiotics and lytic agents in SNEDDS can lead to nanoemulsification of the wider regions themselves in the phase diagram. Pepper water devices and solubilizers frequently used in the formulation of SNEDDS include propylene glycol, polyethylene glycol, polyoxyethylene, lauroglycortum and transcol.(9).

#### AQUEOUS PHASE:

The characteristics of the aqueous phase in which the SNEDDS are introduced will influence the size of the droplets and the stability of the nano emulsions. Consequently, the pH level and ionic strength of the aqueous phase should be considered when preparing the SNEDDS. The self nano-emulsification behavior and the features of the nano emulsions derived from the SNEDDS in various pH levels and electrolyte concentrations of the aqueous phases ought to be assessed based on their intended route of administration (3).

Composition	Examples	
<b>Lipids and oils</b>	<b>Fatty acids</b>	Palmitic acid, Stearic acid, Oleic acid.
	<b>Fatty acid esters</b>	Glyceryl monooleate [Capmul1 GMO, Imwitor1 948, Peceol1], Glyceryl monostearate [Capmul1 GMS-50, Imwitor1 191], Glyceryl monolinoleate [Maisine <sup>TM</sup> 35-1], Glyceryl palmito stearate [Precirol1 ATO 5], Glyceryl behenate [Compritol1 888 ATO] , Ascorbyl palmitate, Medium chain.
	<b>Propyleneglycol esters</b>	Propyleneglycol monolcaprylate [Capryol1 90, Capmul1 PG-8], Propylene glycol dicaprylocaprate [Labrafac1 PG]
	<b>Surfactants/ stabilizers</b>	Caprylocaproyl polyoxyl-8-glycerides [Labrasol1], Polyoxyethylene sorbitan fatty acid esters [Tween1], Polyoxyethylene castor oil derivatives.
	<b>Co-surfactants</b>	Hydroxyl propyl methyl cellulose, Poloxamer, Phospholipids and PEGylated phospholipids.
	<b>co-solubilizers</b>	Polyvinyl pyrrolidone, Bile acids (sodium deoxycholate), Cellulose derivatives, Propylene glycol, Phospholipids, Oleoyl/ linoleoyl polyoxyl-6-glycerides [Labrafil1], Polyethylene glycol, Triacetin, Ethanol, Diethylene glycol monoethyl ether [Transcutol1 HP]

Fig no: 2 composition of SNEDDS

#### FACTORS AFFECTING SNEDDS :

1. Drug Dosage and Type: The

drug, provided in very high doses, is inappropriate for SNEDD, especially if there is no significant solubility in at least one component during the lipophilic phase. Snedds has the greatest difficulty in supplying drug therapy with little solubility in water and lipids (usually those with log P values) (6).

## 2. Polarity of the lipophilic phase:

Drug release from the microemulsion is influenced by factors such as the polarity of the lipid matrix. Hydrophilic lipophilic balance (HLB), fatty acid chain length, and its degree of unsaturation and microorganism molecular weight affect the polarity of the feces. (6).

---

## FORMULATION OF SNEDD:

There are numerous formulations that can be developed in either hard gelatin or combinations that can lead to fine colloidal emulsions, as it contains a variety of liquid or adjuvants with wax-like AIDS, such as oils, biological lipids, hydrophilic and hydrophilic surfactants, and water-soluble cosolvents. Several factors need to be considered when formulating a self-generous drug delivery system: the solubility of the drug in different oils, surfactants, and blood-sucking agents. In addition to creating phase diagrams, the choice of oil, tension, and co-solvent should be affected by the solubility of the drug. SNEDDS formulations are produced by dissolving the drug in a mixture of oils, surfactants, and cosorbent. Including drugs in Snedd is important as it affects the self-milking process to some extent, leading to a change in the ideal ratio of water surface in oil steaming. As a result, effective Snedd solubility studies and designing phase adjustment reviews are required at preformed stages. For longer release of Snedds, the wording is achieved by including polymer or yellow (5).

---

## MECHANISM OF SNEDDS:

The process of self-emulsification is not completely comprehended. Various mechanisms contribute to spontaneous emulsification, which appear to depend on the composition of the system, the physicochemical properties, and the method of emulsification (5). The loose power of a conventional emulsion at once relies upon at the power essential to shape a brand new interface among the oil and water phases. This can be explained as;

$$\Delta G = \Sigma N\pi r^2\sigma$$

Where,

DG represents the free energy linked to the process.

N denotes the quantity of droplets with a certain radius.

r, while S indicates the interfacial energy (9).

Over time, two phases of the emulsion tend to minimize the interface range. As a result, emulsifiers stabilize the emulsion by creating monocitiches around the droplets, reducing interface energy and act as a barrier to coalescence (1). In this scenario, phase separation is simply shifted as these emulsions remain thermodynamically unstable. In the case of self-emulsifying systems, the free energy required to generate the emulsion is very low or even negative, indicating that the formation is thermodynamically spontaneous. The liquid crystal phase between the oil/tension and the water phase reports that it effectively inflates the spontaneous creation of the interface between the oil droplets and water, making spontaneous creation easier. Use particle size analysis and low-frequency dielectric spectroscopy (mixing of caprylic acid mono-, di-glycerides and triglycerides) and Twen 80. Dielectric studies provided indications that emulsion formation could be related to the development of the liquid crystal phase, even if the connections were clearly complicated. This explains the process of creating nanoemulsions when taking snedds (5).




Fig no 3: Mechanism of SNEDDS

### LIMITATIONS OF LIQUID SNEDDS :

The liquid self-emulsifying drug delivery system must be administered in soft gelatin capsules or hydroxypropylal METY serose capsules. When these systems are encapsulated, there are several challenges associated with these systems. For example, important production methods including long-term incompatibility of components with capsule shells, defaulting drugs during the manufacturing process, storage at low temperatures, and critical production methods. [44]. Furthermore, SNEDDS may not be effective for hydrophobic drugs that could experience degradation induced by pH changes or in a solution state. (3)

### APPLICATION :

Lipids, surfactants, and cosol events form the wording of Snedds. The system can be mixed with the aqueous phase and exposed to gentle agitation to create an emulsion in water. SEDD provides small droplet medication with even distribution, leading to improved resolution and permeability. The drug can be encapsulated in the internal phase and may be released by lymphatic bypass (6).

### EVALUATION TEST FOR SNEDDS:

#### 1. Thermodynamic Stability Study: The

study is carried out in six exposure cycles at both a cooling temperature of °C and a high temperature of 5°C, with each temperature being held for at least 8 hours. Formulations that remain stable at these temperatures are performed in centrifugation tests. For centrifugation, the stable formulation is exposed to a taush cycle at a temperature of 21°C to 25°C, whereby each temperature is held for at least

8 hours and centrifuged at 3500 rpm for 30 minutes. All formulations without phase separation are sent to the frozen tau voltage test (1).

#### 2. Emulsification Time:

Following the duration of emulsification (time required to preconcentrate for the occurrence of a homogeneous mixture in the case of dilution), we visually noticed three times the possibility of sneading and the appearance of nanoemulsions. The resolution device was used with 500 ml of water and a paddle speed of 50 rpm and held at 37°C. Snedds (1 ml) was pipetted dropwise into the medium and the time to completely disappear from Snedds was recorded (12).

### 3. Fluoostability:

To assess river characteristics, rest times were assessed using fixed funnel technology, in addition to the apparent bulk density, density, Carr-index, and Hausner ratios. The angle of repose was measured by placing graph paper on a level surface and securing a funnel above it, with a gap of about 7–8 cm between the paper and the funnel's top. A sample of powder (2 g) was prepared and poured into the funnel until the apex of the cone-shaped mound just touched the funnel's edge. The height (h) and diameter (D) of the conical pile of powder were recorded, and the angle of repose was computed using the standard equation ( $\tan \alpha = 2h/D$ ). A powder exhibiting an angle of repose below 25° is classified as having excellent flow, whereas a powder with an angle of repose exceeding 40° is deemed to have poor flow (17).

..Conflictability Test: The autoimmune efficacy of oral nano- or microemulsions is assessed using standard ESP resolution device II. The milliliters of each wording are inserted into 500 ml of water and kept at  $37 \pm 0.5^\circ\text{C}$ . Traditional resolution paddles made from 50 rpm stainless steel provide mild movement (13).

### 5. Pharmaceutical Content:

IRBs from refined Snedds formulations were extracted using sonication using methanol. The resulting methanol extract was evaluated for IRB concentration spectrophotometric measurements at a wavelength of 2 nm after appropriate dilution (12).

### 6. Separation Profile:

To assess the release release of Snedds, 10 mg equivalents were placed individually in hard gelatin capsules. The USP Resolution Device II Paddle was stirred at a rate of 50 rpm using a release test at a temperature of  $37 \pm 0.5^\circ\text{C}$  using a pH value of

.5 acetate buffer as the resolution medium. At specific time intervals, 2 mL trial aliquots were extracted (instantly filtered) and fresh medium was introduced to maintain sink conditions. After appropriate dilution with pH values of

.5 acetate buffer, samples were analyzed using a 237 nm UV spectrophotometer. The experiments were performed three times to ensure reliable and accurate results (17).

### 7. Viscosity:

The rheological properties of the microemulsion are evaluated using the Brookfield Visexexter. The determination of viscosity indicates whether the system is water-in-oil (F/O) or oil-in-water (O/W). The low viscosity suggests that the type O/W system has a higher viscosity from W/O type (1).

### 8. Dilution study :

A dilution investigation was conducted to evaluate the impact of dilution on the SNEDDS preconcentrate. In this analysis, the optimized formulation was tested with different dilutions (i.e., 1:50, 1:100, and 1:500) using various diluents (i.e., water, 0.1N HCl, and phosphate buffer pH 7.5), and the droplet sizes were measured (12).

### 9. Drug loading Efficiency %:

To evaluate the drug loading efficiency (%), 100 mg of SNEDDS was placed in 10 ml of methanol and vortexed in an orbital shaker (Remi, India) for 10 minutes. The SNEDDS solution in methanol was analysed directly after appropriate dilution and assessed at 237 nm using a UV spectrophotometer. The other two mixtures were centrifuged at 4000 rpm for 10 minutes, and the supernatant obtained was filtered through Whatman filter paper (0.45 µm nylon). After suitable dilution, these samples were analysed in a UV spectrophotometer, and the process was repeated three times. The drug loading efficiency (%) was determined using the specified formula (17).

Drug loading efficiency (%) = (1) Actual quantity of NIM present in the known amount of formulation / Initial drug (NIM) load  $\times 100$

### 10. Turbidimetric assessment:

Nepheloturbidimetric assessment is performed to observe the development of emulsification. A set amount of the self Nono-emulsifying system is mixed with a specific volume of an appropriate medium (0.1N hydrochloric acid) while being stirred continuously (50 rpm) on a magnetic stirrer at room temperature, and the rise in turbidity is recorded using a turbidimeter (1).

### 11. Drug parameters:

To determine the pharmacokinetic parameters of individual rats in each group, the peak plasma concentration (C<sub>MAX</sub>), the time to achieve C<sub>MAX</sub> (T<sub>MAX</sub>), and the area under plasma concentration under plasma concentration from a point of zero (12 H), and 12 h (12 h), and s (12 h) (12 h) (12 h). Statistical significance was considered in p

## 12.Refractive Index :

The refractive index and percentage transmittance confirmed the clarity of the formulation. The percentage transmittance of the system is assessed at specific wavelengths using a UV spectrophotometer, with distilled water serving as the blank (1).

---

## CONCLUSION:

Snedds provides an effective solution to fix solubility and bioavailability problems associated with water in medicine. Through continuous advances in formulation methods and the selection of auxiliary substances, Snedds continues to play a key role in modern pharmaceutical delivery systems.

---

## RESULTS:

Results also highlight many benefits, such as improved drug stability, simple manufacturing processes, and reduced food effects on drug absorption. Nevertheless, problems such as the stomach caused by surfactants must take into account essential factors, potential drug disorders, and formulation stability. In summary, SNEDD serves as a flexible and efficient platform for oral administration of lipophilic therapeutic compounds.

---

## REFERENCES:

1. Amol Deshmukh. Recent Advances in Self-Emulsifying Drug Delivery Systems. DOI: 10.37285/ijpsn.2015.8.1.1
2. Aristote B. Buya, Ana Beloqui et al. Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery. doi:10.3390/pharmaceutics12121194
3. Mrunal P. Divate, Shravani U et al..SELF NANO-EMULSIFYING DRUG DELIVERY SYSTEM: A REVIEW.
4. Abhijit A Date ,Neha Desai, et al. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances.
5. Abdul Wadood Khan, Sabna Kotta, et al..Potentials and challenges in self-nanoemulsifying drug delivery systems.
6. Ahmad Salawi. Self-emulsifying drug delivery systems: a novel approach to deliver drugs. doi.org/10.1080/10717544.2022.2083724
7. Irina Cherniakov , Abraham J Domb , et al. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.DOI: 10.1517/17425247.2015.999038
8. Fiza Ur Rehman, Kifayat Ullah Shah, et al .From nanoemulsions to self-nanoemulsions, with recent advances in self-nanoemulsifying drug delivery systems (SNEDDS) DOI:10.1080/17425247.2016.1218462.
9. Boontida Moraku. Self-nanoemulsifying drug delivery systems (SNEDDS): an advancement technology for oral drug delivery. DOI:10.29090/psa.2020.03.019.0121
10. N. Thomas, R. Holm, et al., In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).doi:10.1016/j.jconrel.2012.02.027
11. Ruchita Patel, Meghana Kamble, et al. A REVIEW ON SOLID SELF EMULSIFYING DRUG DELIVERY SYSTEM.
12. Jaydeep Patel, Anjali Patel ,et al., Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan.DOI 10.4103/2231-4040.79799
13. Aristote B. Buya , Ana Beloqui , et al ., Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery. doi:10.3390/pharmaceutics12121194
14. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability Kanchan Kohli, Sunny Chopra, et al ., doi:10.1016/j.drudis.2010.08.007.
15. Sara Meirinho, Márcio Rodrigues, et al., Self-Emulsifying Drug Delivery Systems: An Alternative Approach to Improve Brain Bioavailability of Poorly Water-Soluble Drugs through Intranasal Administration. doi org/10.3390/pharmaceutics14071487.
16. Lijuan Wang, Jinfeng Dong , et al ., Design and optimization of a new self-nanoemulsifying drug delivery system. doi:10.1016/j.jcis.2008.10.077
17. Mohit Kumar Pooja A. Chawla, et al., Solid self-nanoemulsifying drug delivery systems of nimodipine: development and evaluation.,doi.org/10.1186/s43094-024-00653-x.